Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - How to prevent M&A heartburn

This article was originally published in Scrip

Executive Summary

Many champions of the pharmaceutical industry achieved scale and global reach through mergers and acquisitions. Indeed, the M&A remains a robust strategy for companies of all sizes looking for innovation, greater efficiencies or commercial advantage. Yet the integration of separate organisations is fraught with challenges that can undermine the very drivers for doing the deal, explain Dorene Lynch, Greg Kain and Alvin Doss, Jr.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel